Donate

The Development of A Novel Blood Biomarker for Detecting AR-V7 and Resistance to Zytiga and Xtandi

At the current AUA Annual Meeting going on in New Orleans, there was a presentation given by Haitao Zhang and colleagues. They described their work developing a novel blood-based assay (test) for detecting androgen receptor (AR) splice variants in men with advanced prostate cancer. Their work relies on the premise that AR-V7 expression underlies resistance [...]

ADJUVANT AND SALVAGE RADIOTHERAPY AFTER PROSTATECTOMY: NEW ASTRO/AUA GUIDELINE

A joint task force composed of members from the American Urological Association (AUA) and the American Society for Radiation Oncology (ASTRO) has presented formal guidelines for the use of adjuvant and salvage radiation after a radical prostatectomy. To construct the Guideline they relied on a systematic review of the literature using the Pubmed, Embase and [...]

The AUA Issues Specific Guidelines for the Treatment of Men with Castrate Resistant Prostate Cancer

There was a lot of interesting and important presentations at the recent American Urological Association meeting, however the one item that will have the most impact on men with advanced prostate cancer is the new guidelines that were proposed for the treatment of men with castrate resistant prostate cancer. The guidelines were organized by creating [...]

An Important Fact from the 2010 AUA Meeting

Findings from the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial indicate that the strongest predictors of prostate cancer-specific mortality include Gleason 7, body mass index >30, African-American race, PSA level, stage, and high co-morbidity score. Understanding how non-tumor factors affect prostate cancer-specific mortality will help identify those men who may benefit from screening and [...]

Go to Top